ClinicalTrials.gg
RecruitingNCT06939335Lazarus-PEEPUpdated Jan 21, 2026

The Application of Positive End-Expiratory Pressure in Out-of-Hospital Cardiac Arrest: The Lazarus-PEEP Trial.

A Phase 3 interventional study of Disposable PEEP Valve set at 5 cm H20. and Controle in Cardiac Arrest (CA), Out-of-hospital Cardiac Arrest (OHCA) and Positive End-expiratory Pressure (PEEP), sponsored by University Hospital, Ghent. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Primary conditionOut-of-Hospital Cardiac ArrestRegistry: Heart ArrestReclassifiedWhy we changed it
Registry
Heart Arrest — the first condition term the registry derived for this study.
ClinicalTrials.gg
Out-of-Hospital Cardiac Arrest
Why
  1. The study's listed conditions name Out-of-Hospital Cardiac Arrest, a narrower term within Heart Arrest.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Ghent · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Out-of-Hospital Cardiac Arrest with a site in Belgium — 4 open to participants now, 5 under way, 1 of them phase 3. Out-of-Hospital Cardiac Arrest · Belgium.

Started
2025
with 1 other
Phase 3
Only one
of the 13
Registered
10th of 13
by date
Lead sponsor
3 of 13
University Hospital, Ghent

Among the 13 studies in Out-of-Hospital Cardiac Arrest with a site in Belgium, this one is one of 2 that started in 2025, is the only one in phase 3, and was the 10th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

4 of the 13 studies in Out-of-Hospital Cardiac Arrest with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Out-of-Hospital Cardiac Arrest with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether using Positive End-Expiratory Pressure (PEEP) during cardiopulmonary resuscitation (CPR) improves outcomes for adults who experience out-of-hospital cardiac arrest, a condition where the heart suddenly stops beating. PEEP is used during ventilation, which may enhance oxygen levels by keeping the airways open throughout CPR.

This study aims to determine if using PEEP during CPR helps restart the heart more effectively, improves survival rates, and enhances survival with good neurologic outcomes after a cardiac arrest compared to standard CPR without PEEP.

Researchers will randomly assign participants to one of two groups: one receiving CPR with PEEP set at 5 cm of water pressure and the other receiving standard CPR without PEEP. Participants will be treated by emergency medical teams trained in advanced life support, and specialised sensors will measure airflow and airway pressure during resuscitation.

Additionally, the study will evaluate potential side effects associated with PEEP, such as increased pressure within the chest or lung injuries. Findings from this trial will guide recommendations on the usage of PEEP in standard CPR practices to potentially improve patient outcomes.

Read the detailed description

Introduction: Sudden cardiac arrest is a significant cause of mortality, with an estimated annual incidence of 84 cases per 100,000 individuals in Europe. Effective cardiopulmonary resuscitation (CPR), including proper ventilation, is crucial for survival. However, the interplay between ventilation and circulation during CPR is complex and not fully understood. While ventilation is necessary for oxygenation, excessive hyperventilation and high intrathoracic pressures can be detrimental. Positive End-Expiratory Pressure (PEEP) may improve oxygenation and ventilation by maintaining alveolar patency and improving oxygenation. Previous observational studies have suggested that PEEP might enhance the rate of Return of Spontaneous Circulation (ROSC) and improve short-term outcomes. However, no prospective randomised clinical trials have been conducted to confirm these findings. The Lazarus-PEEP trial aims to address this gap by evaluating the efficacy and safety of PEEP during CPR for out-of-hospital cardiac arrest (OHCA) patients.

Methodology: The study will be conducted at Ghent University Hospital and three non-university hospitals in Belgium, enrolling adult patients who experience non-traumatic OHCA and are intubated and ventilated during resuscitation efforts by an advanced life support (MUG) team. Participants will be randomised to receive either PEEP at 5 cm H2O or no PEEP (0 cm H2O) during CPR. Custom-built sensors will measure tracheal airflow and pressure, while additional data on CPR quality and patient outcomes will be collected. The trial's primary outcome measure is the rate of ROSC, with secondary outcomes including survival to hospital admission and discharge, as well as neurological outcomes at discharge.

Outcome: The study will evaluate the effectiveness of PEEP in improving ROSC rates, short-term survival, and neurological outcomes. Safety profiles will also be examined, focusing on adverse effects such as barotrauma and increased intrathoracic pressures. Comprehensive data collection will provide insights into the physiological impact of PEEP during CPR and its feasibility in a pre-hospital setting.

Conclusion: The Lazarus-PEEP trial aims to gather strong evidence on the potential advantages and risks of utilizing PEEP during CPR for OHCA patients. The results will inform evidence-based guidelines and enhance resuscitation practices, potentially leading to improved patient outcomes. The findings will be disseminated through influential journals, major scientific conferences, and public data-sharing platforms to ensure widespread accessibility and impact.

03

Conditions studied

  • Cardiac Arrest (CA)
  • Out-of-hospital Cardiac Arrest (OHCA)
  • Positive End-expiratory Pressure (PEEP)
  • Ventilation During Resuscitation

Browse trials for

04

In context

Out-of-Hospital Cardiac Arrest Reclassified

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

This study's planned enrollment of 132 is below the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.

Browse Out-of-Hospital Cardiac Arrest studies →

Lead sponsor

University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Compared within Out-of-Hospital Cardiac Arrest, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Arrest. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: Adults aged 18 years and older.
  2. Type of Cardiac Arrest: Patients who have experienced a non-traumatic out-of-hospital cardiac arrest.
  3. CPR Administration: Patients receiving cardiopulmonary resuscitation from an advanced life support (ALS) team.
  4. Intubation and Ventilation: Patients who are intubated and ventilated during resuscitation efforts.

Exclusion criteria

Exclusion Criteria:

  1. Cardiac arrest in patient younger than 18 years of age.
  2. Traumatic cardiac arrest, including drowning, penetrating or blunt injury, and burns.
  3. Immediate Return of Spontaneous Circulation (ROSC): Patients who achieve ROSC before intubation and initiation of intubation.
  4. Pregnancy.
  5. Mechanical ventilation during arrest: patients already receiving mechanical ventilation at the moment of cardiac arrest, due to reasons other than their arrest, will be excluded.
  6. Do Not Resuscitate (DNR) Orders: Patients with existing DNR orders or any advanced directive indicating that CPR should not be performed.
  7. Failure to intubate: if intubation is unsuccessful, ventilation by any means (MBV, SGA) should take priority over the study protocol, and the patient is excluded.
  8. Enrolment in Other Studies: Patients currently enrolled in another interventional clinical trial that could interfere with the outcomes of this study.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Intervention

    Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 and a disposable PEEP Valve set at 5 cm H20.

    Device: Disposable PEEP Valve set at 5 cm H20.

  • Active comparator
    Controle

    Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 without a disposable PEEP Valve.

    Device: Controle

Interventions

  • DeviceDisposable PEEP Valve set at 5 cm H20.

    Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 and a 22 mm disposable PEEP Valve set at 5 cm H20.

  • DeviceControle

    Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 without a disposable PEEP Valve.

07

What researchers measure

Primary outcomes

  1. Return of spontaneous circulation (ROSC)

    The occurrence of Return of spontaneous circulation (ROSC), defined as the return of sustained spontaneous circulation for at least 20 minutes per ERC guidelines

    Time frame: Day one

Secondary outcomes

  1. Survival to hospital admission

    Time frame: Day one

  2. Survival to hospital discharge

    Time frame: From enrolment until hospital discharge or death - whichever happens first. Average hospitalisation after OHCA is 24 days.

  3. 30-day survival

    Time frame: From enrollment to the end of 30 days.

  4. 90-day survival

    Time frame: From enrollment to the end of 90 days.

  5. Neurological outcome at discharge

    Neurological outcome at discharge, as defined by the Cerebral Performance Category Scale.

    Time frame: From enrolment until hospital discharge or death - whichever happens first. Average hospitalisation after OHCA is 24 days.

Other outcomes

  1. Airflow during ventilation

    The Sensirion SFM3200AW flow sensor will measure airflow during cardiopulmonary resuscitation, measured in ml.

    Time frame: Periprocedural

  2. Airway pressure during ventilation

    The Wika CPT2500 sensor will measure airway pressure during cardiopulmonary resuscitation, measured in mbar.

    Time frame: Periprocedural

  3. Occurence of potential adverse effects

    The incidence of barotrauma, including pneumothorax and pneumomediastinum

    Time frame: Day one

  4. Capnography

    the ZOLL® X Series® monitor-defibrillator will be used to collect capnography data during cardiopulmonary resuscitation, measured in mmHg.

    Time frame: Periprocedural

  5. Compression depth

    The ZOLL® X Series® monitor-defibrillator will be used to measure Compression depth, measured in mm.

    Time frame: Periprocedural

  6. Compression frequency

    The ZOLL® X Series® monitor-defibrillator will be used to measure Compression frequency, measured in compressions/minute.

    Time frame: Periprocedural

08

Study locations

6 of 7 sites recruiting
  • AZ Oostende
    Ostend, West-Flandres 8400, Belgium
    Recruiting
  • AZORG: campus Merestraat
    Aalst, B-9300, Belgium
    Recruiting
    • AZORG: campus Merestraat · Contactspoedopname.asz@azorg.be · 0032 53 76 40 06
    • Jolien Volcke, MD · Principal investigator
  • AZORG: Campus Moorselbaan
    Aalst, B-9300, Belgium
    Recruiting
    • AZORG: Campus Moorselbaan · Contact0032 53 72 49 96
    • Thomas Tackaert, MD · Principal investigator
  • AZORG: campus Geraardsbergen
    Geraardsbergen, B-9500, Belgium
    Recruiting
    • AZORG: campus Geraardsbergen · Contactspoedopname@azorg.be · 0032 54 43 27 11
    • Jolien Volcke, MD · Principal investigator
  • UZ Ghent
    Ghent, B-9240, Belgium
    Recruiting
    • Spoedgevallendienst UZ Gent · Contactsecretariaatspoed@uzgent.be · 0032 9 332 50 24
    • Saïd Hachimi Hachimi Idrissi, MD, PhD, Professor · Principal investigator
    • Sarah Ballet · Sub investigator
    • Tom Coucke, MD · Sub investigator
    • Hannah Van Belleghem, MD · Sub investigator
  • AZ Zeno
    Knokke, 8300, Belgium
    Recruiting
    • Urgentiegeneeskunde - spoed AZ Zeno Knokke-Heist · Contactinfo@azzeno.be · 0032 50 535 112
    • Tom De Coninck, MD · Principal investigator
  • Centre hospitalier universitaire (CHU) Besançon-Franche-Comté
    Besançon, France
    Active, not recruiting

    Not enrolling at this site.

09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 22, 2025
StartActual
Apr 25, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Feb 1, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06939335
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Apr 25, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Thomas Tackaert, MD
Contact
thomas.tackaert@ugent.be
0032 53 72 49 96
Saïd Hachimi Idrissi, MD, PhD, Professor
principal investigator · UZ Gent

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion